JP2025508073A - ＴＧＦ－β抗体 - Google Patents

ＴＧＦ－β抗体 Download PDF

Info

Publication number
JP2025508073A
JP2025508073A JP2024553443A JP2024553443A JP2025508073A JP 2025508073 A JP2025508073 A JP 2025508073A JP 2024553443 A JP2024553443 A JP 2024553443A JP 2024553443 A JP2024553443 A JP 2024553443A JP 2025508073 A JP2025508073 A JP 2025508073A
Authority
JP
Japan
Prior art keywords
seq
tgf
amino acid
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508073A5 (https=
Inventor
マリエン，ローレ
ベック，ジッテ デ
ルーカス，ソフィー
ランバート，ファニー
ダー ウォニング，セバスチャン ポール ヴァン
リエナール，ステファニー
Original Assignee
ウニベルシテ カソリーク デ ルーベン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルシテ カソリーク デ ルーベン filed Critical ウニベルシテ カソリーク デ ルーベン
Publication of JP2025508073A publication Critical patent/JP2025508073A/ja
Publication of JP2025508073A5 publication Critical patent/JP2025508073A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024553443A 2022-03-09 2023-03-09 ＴＧＦ－β抗体 Pending JP2025508073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2203269.2A GB202203269D0 (en) 2022-03-09 2022-03-09 TGF-Beta antibodies
GB2203269.2 2022-03-09
PCT/EP2023/056082 WO2023170241A1 (en) 2022-03-09 2023-03-09 TGF-β ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2025508073A true JP2025508073A (ja) 2025-03-21
JP2025508073A5 JP2025508073A5 (https=) 2026-03-13

Family

ID=81175458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553443A Pending JP2025508073A (ja) 2022-03-09 2023-03-09 ＴＧＦ－β抗体

Country Status (9)

Country Link
US (1) US20250188161A1 (https=)
EP (1) EP4490186A1 (https=)
JP (1) JP2025508073A (https=)
CN (1) CN119173533A (https=)
AU (1) AU2023229972A1 (https=)
CA (1) CA3245104A1 (https=)
GB (1) GB202203269D0 (https=)
IL (1) IL315033A (https=)
WO (2) WO2023170241A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
ES2860952T3 (es) 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
EP3139957A4 (en) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
AU2018387829B2 (en) 2017-12-22 2024-12-19 Argenx Bvba Bispecific antigen binding construct

Also Published As

Publication number Publication date
EP4490186A1 (en) 2025-01-15
WO2023170242A1 (en) 2023-09-14
IL315033A (en) 2024-10-01
WO2023170241A1 (en) 2023-09-14
GB202203269D0 (en) 2022-04-20
CN119173533A (zh) 2024-12-20
AU2023229972A1 (en) 2024-09-12
CA3245104A1 (en) 2023-09-14
US20250188161A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
JP7679430B2 (ja) Ｇｐｒｃ５ｄに結合する抗体
US11242404B2 (en) Antibodies against signal-regulatory protein alpha and methods of use
US20240067734A1 (en) Antibodies binding to NKG2D
US20220411491A1 (en) Antibodies binding to gprc5d
JP7366897B2 (ja) 抗ｔｉｇｉｔ抗体
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN114828965B (zh) 与hla-a2/mage-a4结合的抗体
TW201936641A (zh) 結合gprc5d之抗體
CN111526888A (zh) 抗tigit抗体及其作为治疗和诊断的用途
WO2019152715A1 (en) Anti-ms4a4a antibodies and methods of use thereof
CN113583128A (zh) 抗garp蛋白及其用途
TW201930356A (zh) 結合hla-a2/wt1之抗體
WO2018219327A1 (zh) 抗cd40抗体、其抗原结合片段及其医药用途
KR20210113282A (ko) 항-tigit 항체
CN116375869A (zh) TGF-β-RII结合蛋白质
JP2022505144A (ja) Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
CA3156080A1 (en) LIF SPECIFIC BINDING MOLECULE AND ITS USE
KR20260051068A (ko) Enpp3 및 cd3 결합제 및 이의 사용 방법
US20250188161A1 (en) TGF-ß ANTIBODIES
WO2021180676A1 (en) MuSK AGONIST ANTIBODY
CN121969650A (zh) Ror1抗体的糖工程化形式和使用方法
HK40061355A (en) Antibodies binding to gprc5d
CN115698078A (zh) 人源化抗人cd89抗体及其用途
HK40034438A (zh) 抗ms4a4a抗体及其使用方法
EA045372B1 (ru) Анти-tigit антитела

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260305